Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen

This study has been withdrawn prior to enrollment.
(Sponsor has decided to not proceed with this study.)
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00918450
First received: May 22, 2009
Last updated: February 25, 2010
Last verified: February 2010
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)